Therapeutic Potential of NTRK3 Inhibition in Desmoplastic Small Round Cell Tumor
- 23 November 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 27 (4), 1184-1194
- https://doi.org/10.1158/1078-0432.ccr-20-2585
Abstract
Purpose: Desmoplastic small round cell tumor (DSRCT) is a highly lethal intra-abdominal sarcoma of adolescents and young adults. DSRCT harbors a t(11;22)(p13:q12) that generates the EWSR1-WT1 chimeric transcription factor, the key oncogenic driver of DSRCT. EWSR1-WT1 rewires global gene expression networks and activates aberrant expression of targets that together mediate oncogenesis. EWSR1-WT1 also activates a neural gene expression program. Experimental Design: Among these neural markers, we find prominent expression of neurotrophic tyrosine kinase receptor 3 (NTRK3), a druggable receptor tyrosine kinase. We investigated the regulation of NTRK3 by EWSR1-WT1 and its potential as a therapeutic target in vitro and in vivo, the latter using novel patient-derived models of DSRCT. Results: We find that EWSR1-WT1 binds upstream of NTRK3 and activates its transcription. NTRK3 mRNA is highly expressed in DSRCT compared to other major chimeric transcription factor-driven sarcomas and most DSRCT are strongly immunoreactive for NTRK3 protein. Remarkably, expression of NTRK3 kinase domain mRNA in DSRCT is also higher than in cancers with NTRK3 fusions. Abrogation of NTRK3 expression by RNAi silencing reduces growth of DSRCT cells and pharmacologic targeting of NTRK3 with entrectinib is effective in both in vitro and in vivo models of DSRCT. Conclusions: Our results indicate that EWSR1-WT1 directly activates NTRK3 expression in DSRCT cells, which are dependent on its expression and activity for growth. Pharmacologic inhibition of NTRK3 by entrectinib significantly reduces growth of DSRCT cells both in vitro and in vivo, providing a rationale for clinical evaluation of NTRK3 as a therapeutic target in DSRCT.Keywords
Other Versions
Funding Information
- NCI (P30 CA008748)
- NCI (R01CA222856)
This publication has 40 references indexed in Scilit:
- A Novel Wilms Tumor 1 (WT1) Target Gene Negatively Regulates the WNT Signaling PathwayOnline Journal of Public Health Informatics, 2010
- The EWSR1/NR4A3 fusion protein of extraskeletal myxoid chondrosarcoma activates the PPARG nuclear receptor geneThe Journal of Pathology, 2008
- Outpatient and Home Chemotherapy with Novel Local Control Strategies in Desmoplastic Small Round Cell TumorSarcoma, 2008
- Adenosine Transporter ENT4 Is a Direct Target of EWS/WT1 Translocation Product and Is Highly Expressed in Desmoplastic Small Round Cell TumorPLOS ONE, 2008
- TFE3 Fusions Activate MET Signaling by Transcriptional Up-regulation, Defining Another Class of Tumors as Candidates for Therapeutic MET InhibitionCancer Research, 2007
- Disialoganglioside GD2 and a novel tumor antigen: Potential targets for immunotherapy of desmoplastic small round cell tumorMedical and Pediatric Oncology, 2002
- The EWS-WT1 translocation product induces PDGFA in desmoplastic small round-cell tumourNature Genetics, 1997
- The IGF-I Receptor Gene Promoter Is a Molecular Target for the Ewing's Sarcoma-Wilms' Tumor 1 Fusion ProteinOnline Journal of Public Health Informatics, 1996
- Cytogenetic abnormalities in an intraabdominal desmoplastic small cell tumorCancer Genetics and Cytogenetics, 1992
- Case 2 Desmoplastic Small Cell Tumor with Divergent DifferentiationPediatric Pathology, 1989